Innoviva Return on Investment 2004-2025 | INVA
Current and historical return on investment (ROI) values for Innoviva (INVA) over the last 10 years.
| Innoviva ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2025-06-30 |
$0.18B |
$0.97B |
18.78% |
| 2025-03-31 |
$0.18B |
$0.90B |
18.72% |
| 2024-12-31 |
$0.17B |
$0.95B |
16.15% |
| 2024-09-30 |
$0.16B |
$0.93B |
15.04% |
| 2024-06-30 |
$0.14B |
$1.11B |
12.30% |
| 2024-03-31 |
$0.11B |
$1.15B |
10.22% |
| 2023-12-31 |
$0.12B |
$1.12B |
10.95% |
| 2023-09-30 |
$0.10B |
$1.07B |
9.88% |
| 2023-06-30 |
$0.37B |
$1.00B |
36.28% |
| 2023-03-31 |
$0.43B |
$1.01B |
41.46% |
| 2022-12-31 |
$0.47B |
$1.01B |
46.26% |
| 2022-09-30 |
$0.56B |
$1.09B |
55.36% |
| 2022-06-30 |
$0.36B |
$1.01B |
37.91% |
| 2022-03-31 |
$0.38B |
$1.00B |
41.85% |
| 2021-12-31 |
$0.38B |
$0.92B |
40.95% |
| 2021-09-30 |
$0.36B |
$0.88B |
38.02% |
| 2021-06-30 |
$0.35B |
$0.78B |
36.52% |
| 2021-03-31 |
$0.32B |
$1.08B |
33.50% |
| 2020-12-31 |
$0.32B |
$0.99B |
35.97% |
| 2020-09-30 |
$0.31B |
$0.92B |
37.62% |
| 2020-06-30 |
$0.29B |
$0.87B |
37.64% |
| 2020-03-31 |
$0.27B |
$0.79B |
38.59% |
| 2019-12-31 |
$0.25B |
$0.72B |
37.87% |
| 2019-09-30 |
$0.25B |
$0.67B |
41.12% |
| 2019-06-30 |
$0.25B |
$0.63B |
48.60% |
| 2019-03-31 |
$0.25B |
$0.59B |
57.77% |
| 2018-12-31 |
$0.24B |
$0.54B |
67.42% |
| 2018-09-30 |
$0.23B |
$0.27B |
75.50% |
| 2018-06-30 |
$0.21B |
$0.33B |
65.12% |
| 2018-03-31 |
$0.20B |
$0.27B |
59.95% |
| 2017-12-31 |
$0.18B |
$0.33B |
52.40% |
| 2017-09-30 |
$0.16B |
$0.36B |
43.66% |
| 2017-06-30 |
$0.14B |
$0.34B |
40.37% |
| 2017-03-31 |
$0.12B |
$0.37B |
33.75% |
| 2016-12-31 |
$0.11B |
$0.36B |
30.58% |
| 2016-09-30 |
$0.09B |
$0.35B |
24.15% |
| 2016-06-30 |
$0.07B |
$0.36B |
17.89% |
| 2016-03-31 |
$0.05B |
$0.37B |
11.79% |
| 2015-12-31 |
$0.03B |
$0.39B |
7.18% |
| 2015-09-30 |
$0.01B |
$0.42B |
3.05% |
| 2015-06-30 |
$0.00B |
$0.44B |
-0.83% |
| 2015-03-31 |
$-0.02B |
$0.47B |
-3.73% |
| 2014-12-31 |
$-0.04B |
$0.50B |
-6.62% |
| 2014-09-30 |
$-0.02B |
$0.51B |
-2.91% |
| 2014-06-30 |
$-0.01B |
$0.55B |
-2.43% |
| 2014-03-31 |
$-0.01B |
$0.55B |
-1.91% |
| 2013-12-31 |
$-0.03B |
$0.59B |
-5.04% |
| 2013-09-30 |
$-0.08B |
$0.62B |
-15.26% |
| 2013-06-30 |
$-0.10B |
$0.55B |
-23.25% |
| 2013-03-31 |
$-0.13B |
$0.55B |
-33.25% |
| 2012-12-31 |
$-0.01B |
$0.33B |
-4.28% |
| 2012-09-30 |
$-0.02B |
$0.35B |
-7.82% |
| 2012-06-30 |
$-0.02B |
$0.36B |
-8.12% |
| 2012-03-31 |
$0.00B |
$0.18B |
-2.34% |
| 2011-12-31 |
$-0.11B |
$0.09B |
-92.05% |
| 2011-09-30 |
$-0.09B |
$0.11B |
-67.77% |
| 2011-06-30 |
$-0.08B |
$0.14B |
-72.02% |
| 2011-03-31 |
$-0.08B |
$0.15B |
-83.65% |
| 2010-12-31 |
$-0.08B |
$0.15B |
-108.33% |
| 2010-09-30 |
$-0.08B |
$0.03B |
-265.57% |
| 2010-06-30 |
$-0.08B |
$0.05B |
-368.54% |
| 2010-03-31 |
$-0.08B |
$0.06B |
-610.91% |
| 2009-12-31 |
$-0.08B |
$-0.02B |
-1350.00% |
| 2009-09-30 |
$-0.08B |
$0.00B |
-384.62% |
| 2009-06-30 |
$-0.08B |
$0.01B |
-234.38% |
| 2009-03-31 |
$-0.08B |
$0.03B |
-184.09% |
| 2008-12-31 |
$-0.09B |
$0.04B |
-162.45% |
| 2008-09-30 |
$-0.11B |
$0.05B |
-358.40% |
| 2008-06-30 |
$-0.13B |
$0.06B |
-1362.16% |
| 2008-03-31 |
$-0.15B |
$0.08B |
1507.69% |
| 2007-12-31 |
$-0.17B |
$-0.07B |
676.00% |
| 2007-09-30 |
$-0.18B |
$-0.04B |
-2346.67% |
| 2007-06-30 |
$-0.18B |
$-0.02B |
-441.21% |
| 2007-03-31 |
$-0.18B |
$0.02B |
-233.99% |
| 2006-12-31 |
$-0.18B |
$0.06B |
-161.63% |
| 2006-09-30 |
$-0.18B |
$0.10B |
-165.83% |
| 2006-06-30 |
$-0.18B |
$0.13B |
-162.53% |
| 2006-03-31 |
$-0.17B |
$0.16B |
-148.67% |
| 2005-12-31 |
$-0.15B |
$0.06B |
-130.42% |
| 2005-09-30 |
$-0.14B |
$0.10B |
-92.36% |
| 2005-06-30 |
$-0.12B |
$0.14B |
-80.00% |
| 2005-03-31 |
$-0.12B |
$0.16B |
-101.51% |
| 2004-12-31 |
$-0.11B |
$0.19B |
-140.40% |
| 2004-09-30 |
$-0.09B |
$0.11B |
-334.55% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$0.953B |
$0.331B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
